Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA’s RMAT designation and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results